Search | Clinical Trials Finder

Conditions: Diabetes, End Stage Renal Disease
Interventions: EchoMark/EchoSure, Standard of Care; Device · Procedure
Lead sponsor: Sonavex, Inc.; Industry
Eligibility: 18 Years to 84 Years
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 21
States / cities: Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 17 more

Conditions: Glioblastoma, Glioblastoma Multiforme
Interventions: EGFR BATs with TMZ following SOC RT/TMZ, Weekly EGFR BATs following SOC RT/TMZ; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: High Grade Glioma
Interventions: O-(2-[18F]Fluoroethyl)-L-tyrosine, [18F]-FET with PET/MRI; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 10 Years to 89 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: COVID-19
Interventions: Baricitinib, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,525 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 25
States / cities: Gilbert, Arizona • Phoenix, Arizona • Newport Beach, California + 20 more

Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions: Best Practice, Patient Navigation; Other · Behavioral
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Imaging
Interventions: C-arm PCD-CBCT; Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Localized Breast Carcinoma
Interventions: Lymphedema Management, Questionnaire Administration, Adjuvant breast radiation therapy; Other · Radiation
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Chronic Hepatitis C Genotype-1 Relapse
Interventions: NIM811, Placebo BID + SOC; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 69 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 5
States / cities: San Diego, California • Orlando, Florida • Sarasota, Florida + 2 more

Conditions: Rare Diseases
Interventions: clinical whole genome sequencing (cWGS); Other
Lead sponsor: Illumina, Inc.; Industry
Eligibility: 1 Day to 120 Days
Enrollment: 355 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 5
States / cities: Orange, California • St Louis, Missouri • Omaha, Nebraska + 2 more

Conditions: Lupus Erythematosus, Systemic
Interventions: Litifilimab, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 548 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 53
States / cities: Homewood, Alabama • Beverly Hills, California • Los Angeles, California + 46 more

Conditions: Atopic Dermatitis
Interventions: Not listed
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 46
States / cities: Birmingham, Alabama • Montgomery, Alabama • Gilbert, Arizona + 43 more

Conditions: Breast Cancer
Interventions: ClearEdge device; Device
Lead sponsor: LS BioPath; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Uveitis, Infectious Disease
Interventions: Metagenomic Deep Sequencing (MDS), Standard of Care (SOC); Device · Diagnostic Test
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Partial-thickness Burn Wounds
Interventions: Intact fish skin graft, autograft; Device · Procedure
Lead sponsor: Kerecis Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Gastroschisis
Interventions: SoC Staged Silo Closure, Peritoneal Dialysis Solution/Dextrose 1.5%; Procedure · Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 0 Hours to 12 Hours
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions, Neoplasms
Interventions: LY3537021, Placebo, Standard of Care Antiemetic Therapies, Background Chemotherapy; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 21
States / cities: Greenbrae, California • Irvine, California • Los Alamitos, California + 18 more

Conditions: Endometrial Cancer
Interventions: Trastuzumab deruxtecan, Rilvegostomig, Pembrolizumab, Carboplatin, Paclitaxel, Docetaxel; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 61
States / cities: Tucson, Arizona • Little Rock, Arkansas • Duarte, California + 55 more

Conditions: Neoplasms
Interventions: GSK5764227, Bevacizumab, Fluorouracil, leucovorin, Enzalutamide; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 5
States / cities: Reunion, Florida • New Hyde Park, New York • Philadelphia, Pennsylvania + 2 more

Conditions: Advanced Non-small Cell Lung Cancer, HER2 Mutation
Interventions: Sevabertinib, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 555 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 25
States / cities: Newport Beach, California • San Diego, California • San Francisco, California + 20 more

Conditions: Obesity
Interventions: Enhanced Care; Behavioral
Lead sponsor: Geisinger Clinic; Other
Eligibility: Female only
Enrollment: 218 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Danville, Pennsylvania

Conditions: Arthritis, Rheumatoid
Interventions: GSK3196165 (Otilimab), Sarilumab, Placebo to GSK3196165/ Sarilumab, csDMARDs; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 46
States / cities: Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 36 more

Conditions: Myelofibrosis, Hematopoietic Cell Transplantation (HCT)
Interventions: Momelotinib; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Ewing Sarcoma, Round Cell Sarcoma With EWSR1-non-ETS Fusion
Interventions: Biospecimen Collection, Chemotherapy, Computed Tomography, Conventional Radiotherapy, Definitive Surgical Resection, Dose-escalated Radiation Therapy, Electronic Health Record Review, External Beam Radiation Therapy, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Radiation Therapy; Procedure · Drug · Radiation + 1 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 2 Years and older
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: Phoenix, Arizona • Rochester, Minnesota

Conditions: Fibrosis Syndrome, Lymphedema, Head &Amp; Neck Cancer, Fibrosis
Interventions: Pravastatin (drug), Pentoxifylline, ketoprofen, Pirfenidoneone, Standard of Care (SOC), tocopherol; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Female only
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial

Phase I EGFR BATs in Newly Diagnosed Glioblastoma

Multiparametic Metabolic and Hypoxic PET/MRI for Disease Assessment in High Grade Glioma

A Study of Baricitinib (LY3009104) in Participants With COVID-19

Clinical Trial Navigation to Increase Participation and Diversity in Cancer Clinical Trials

Evaluation of C-arm PCD-CBCT for Image-Guided Interventions

Manual Lymphatic Drainage Breast Massage in Breast Cancer Patients After Breast Conserving Surgery

Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients

NICUSeq: A Trial to Evaluate the Clinical Utility of Human Whole Genome Sequencing (WGS) Compared to Standard of Care in Acute Care Neonates and Infants

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment

Intraoperative Use of ClearEdge Device in Breast Conserving Surgery

Ocular Pathogen and Transcriptome Investigation Using Comprehensive Sequencing

Evaluating Whether Intact Fish Skin Graft Can Decrease the Need for Autograft in the Treatment of Deep Partial-Thickness Burns

Direct Peritoneal Resuscitation in Gastroschisis

A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Teaching Appropriate Gestational Weight Gain

Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors

Momelotinib During and After HCT in Myelofibrosis

Biologically-Adapted, Dose-Escalated Radiotherapy for the Treatment of Ewing Sarcoma, BEAR Trial

Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)